Biologics are expected to see a double-digit growth. Moving biologics drug administration from hospital to home environment is one of the key trends to shape the future of the global biologics industry. One of the most proven strategy adopted by many biopharmaceutical companies is the combination between PFS with autoinjectors or safety devices, nevertheless there are several requirements to be met in case of combining primary packaging and drug delivery device.
Having the right partner for development and manufacturing will be the key for Biopharmaceutical companies to reduce time to market and project risk.
Terumo’s unique capabilities are integrated into CDMO solutions and offer end to end services starting from primary container and drug-device combination product development, fill & finish, device assembly, regulatory support, and commercial launch.
We would like to highlight this with a case study of a biosimilar drug used in combination with Autoinjector which has been launched globally.
Learning Objectives:
- Understand global market trends for biotech drugs: CDMO perspective
- Terumo’s unique capabilities on polymer PFS, coatings, fill & finish, and device assembly
- Integrated CDMO services and impact on time to market
- Collaboration between Pharma customer and integrated CDMO for successful launch
